Heterozygous FH is a common genetic disorder, inherited in an autosomal dominant pattern, occurring in 1:500 people in most countries; Heterozygous FH is normally treated with statins, bile acid sequestrants or other hypolipidemic agents that lower cholesterol levels.
Homozygous FH is much rarer, occurring in 1 in a million births.
How many patients are there in the US?
according to new release 8/9/12, ...Aegerion hasn’t revealed its pricing plan for lomitapide, but Beer says he expects it will fall in the range of $200,000 to $400,000 per patient per year. The consensus among the analysts covering the company is that Aegerion will bring in $26.5 million in sales next year (2013)...
drug itself is dirty cheap to make...patients outside of US will not be paying anything close to $200,000 per patient per year (maybe $2000 in India/China and other countries the drug prices are much lower or out of IP protected areas; plus through oversea mailing order)